STOCK TITAN

Perceptive discloses 1.99M Praxis (NASDAQ: PRAX) shares in 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Perceptive Advisors LLC and affiliated reporting persons disclosed beneficial ownership of 1,995,986 shares of Praxis Precision Medicines, Inc. common stock, representing 7.2% of the class. The shares are held directly by Perceptive Life Sciences Master Fund, Ltd., with Perceptive Advisors as investment manager and Joseph Edelman as managing member.

The ownership percentage is based on 27,738,892 Praxis common shares outstanding as reported in a Prospectus Supplement filed under Rule 424(b)(5) on January 7, 2026. The reporting persons report shared voting and dispositive power over all 1,995,986 shares and certify the holdings are not for the purpose of changing or influencing control of Praxis.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:02/17/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026

FAQ

What ownership stake in Praxis Precision Medicines (PRAX) did Perceptive report?

Perceptive Advisors and related reporting persons reported beneficial ownership of 1,995,986 shares of Praxis Precision Medicines common stock, representing 7.2% of the outstanding class, based on 27,738,892 shares outstanding as disclosed in a January 7, 2026 Prospectus Supplement.

Which entities are the reporting persons in this Praxis (PRAX) Schedule 13G/A?

The reporting persons are Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. The Master Fund directly holds the shares, Perceptive Advisors acts as investment manager, and Edelman is the managing member of Perceptive Advisors.

How many Praxis (PRAX) shares does Perceptive have voting and dispositive power over?

Each reporting person reports shared voting power and shared dispositive power over 1,995,986 Praxis common shares, and no sole voting or dispositive power. All three reporting persons list the same aggregate amount and percentage interest in the issuer’s common stock.

What percentage of Praxis (PRAX) does Perceptive’s 1,995,986 shares represent?

The filing states that 1,995,986 Praxis common shares represent 7.2% of the class. This percentage is calculated using 27,738,892 shares outstanding, as reported in Praxis’s Prospectus Supplement filed under Rule 424(b)(5) on January 7, 2026.

Does Perceptive’s Praxis (PRAX) Schedule 13G/A indicate an intent to influence control?

The certification states the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Praxis. It also notes they are not held in connection with any transaction having that purpose, other than specified proxy nomination activities.

What is the relevant event date for Perceptive’s Praxis (PRAX) holdings in this filing?

The filing lists December 31, 2025 as the Date of Event Which Requires Filing. As of that date, the reporting persons collectively reported beneficial ownership of 1,995,986 shares, equal to 7.2% of Praxis Precision Medicines’ outstanding common stock.
Praxis Precision Medicines, Inc.

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data

8.80B
25.63M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON